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comycin in the treatment of adult CDI patients. The analysis focused on three 
CDI patient subgroups: cancer, concomitant antimicrobials, and renal impaired 
patients. Methods: A Markov model was developed with a cycle length of 10 
days and a one year time horizon. The patient enters the model in the CDI health 
state and is treated with fidaxomicin, or vancomycin for 10 days. Health state 
utilities were derived from the literature. The model perspective was the Spanish 
health care provider. Deterministic and probabilistic sensitivity analyses were 
performed. Results: In all three CDI patient subgroups, fidaxomicin was domi-
nant compared to vancomycin. For cancer fidaxomicin resulted in cost savings of 
€ 2,397 with an incremental QALY gain of 0.016. For concomitant antibiotics fidax-
omicin resulted in cost savings of € 1,452 with an incremental QALY gain of 0.014. 
For renally impaired, fidaxomicin resulted in cost savings of € 1,432 and an incre-
mental QALY gain of 0.013. The main cost-effectiveness drivers were the recur-
rence rate and length of hospital stay. The probability of fidaxomicin being cost 
effective at the € 30,000 threshold was 96%, 94% and 96% respectively for cancer, 
concomitant antimicrobials and renal impairment, respectively. ConClusions: 
Fidaxomicin was dominant compared to vancomycin for these adult CDI patient 
subgroups.
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objeCtives: We aimed at estimating the impact of extending the French influ-
enza vaccination programme from at-risk/elderly (≥ 65 years) only, to additionally 
include children (2-17 years). Methods: A deterministic, age-structured, dynamic 
transmission model was used to simulate the transmission of influenza in the 
French population, under the current coverage with the trivalent inactivated vac-
cine (TIV) in at-risk/elderly individuals (= reference strategy) or after extending 
the coverage to healthy 2-17 years-old children with an intranasal, quadrivalent 
live-attenuated influenza vaccine (QLAIV) (= evaluated strategy). The transmis-
sion probabilities were determined using between-individuals contact patterns 
(“Polymod” matrix). Epidemiological, medical resources and costs data were issued 
by crossing data from literature and French resource-based value scales. The basic 
reproduction number (R0) of the model was calibrated to the observed numbers 
of influenza-like illness visits/year and deaths/year. The 10-year, undiscounted, 
number of symptomatic cases of confirmed influenza and direct medical costs 
(All-payer) were calculated for the 0-17 (direct effect) and ≥ 18 years-old (indirect 
effect). The incremental cost-effectiveness ratio (ICER) was calculated for the total 
population, using a 4% discount/year. Univariate and probabilistic sensitivity anal-
yses were performed. Results: Model calibration yielded R0= 1.27 (assuming 2.3 
million visits/year and 1,960 deaths/year). In the 0-17 years-old with 50% QLAIV 
coverage, the average number of confirmed influenza cases dropped by 865,000/
year, averting 58.4% of the cases occurring in the reference strategy and leading 
to 10-year savings of € 374 million. In the ≥ 18 years-old with unchanged TIV cover-
age, 1.2 million cases/year of confirmed influenza were averted (-27.6%), yielding 
additional 10-year savings of € 457 million. On average, 613 flu-related deaths were 
avoided annually. The ICER was € 18,000/life-year gained. The evaluated strategy 
was 98% cost-effective at a € 30,000/life-year gained threshold. ConClusions: The 
model demonstrated the direct and indirect benefits of protecting healthy children 
against influenza with QLAIV, on public health and economic outcomes in France.
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objeCtives: Multidrug-resistant tuberculosis (MDR-TB) is designated an orphan 
disease in Germany, where about ~65 patients are infected with multidrug-
resistant tuberculosis (MDR-TB). Regimens consisting of several drugs for up to 
24 months are the current standard of care (SoC) for treatment of MDR-TB. The 
aim of this analysis is to evaluate the costs and effectiveness of adding bedaqui-
line (BDQ) to a background regimen (BR) of the SoC in a German health care 
context. Methods: A cohort based Markov model was used to estimate cost-
effectiveness of bedaquiline plus background regimen (BDQ+BR) vs. BR alone for 
treatment of MDR- and XDR-TB (extensively drug resistant). The effectiveness 
of treatment was evaluated in QALYs, DALYs and life year gained (LYG). Inputs 
into the model were derived from a bedaquiline randomised, placebo controlled 
trial and from published literature. Drug costs (in 2014 euros) were taken from 
the German drug directory; a yearly discount rate of 3% was applied and a time 
horizon of 10 years was assumed. Sensitivity analyses were performed to evalu-
ate the impact of model parameters. Results: For a base-case analysis with a 
cohort of 65 MDR-TB patients, adding bedaquiline to BR results in higher costs 
compared to BR alone (4,5 vs. 2,4 MM € ), but yields better outcomes (66 QALYs 
gained). The incremental cost per QALY gained (ICER) was calculated as 33.357 
€ . For a cohort exclusively of XDR-TB patients, the ICER was calculated as 17.915 
€ . To evaluate the impact of model parameters, further sensitivity analyses were 
performed. ConClusions: Adding bedaquiline to a background regimen of anti-
TB drugs is cost-effective, probably even cost saving for patients with MDR- and 
XDR-TB, when compared to BR alone under different cost scenarios. Over a ten 
year period, cost savings were mostly achieved by lesser time of hospitalisation, 
although BDQ+BR drug costs are higher than BR alone.
and dominant in patients with a severe CDI recurrence from a Swedish health 
care perspective.
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objeCtives: Appropriate and timely empiric treatment is very essential for methi-
cillin-resistant Staphylococcus aureus (MRSA) -related infections. Inadequate empiric 
treatment is associated with increased mortality and longer hospital stay. This study 
compares economic impact of initial empiric linezolid (Emp-LIN) vs. vancomycin 
(Emp-VAN) vs. no empiric MRSA coverage (NE-MRSA) before culture-confirmed 
treatment, for suspected MRSA nosocomial pneumonia (NP). Methods: A 4 week 
decision model was developed capturing empiric, 1st and 2nd line therapy. Published 
literature and expert opinion provided clinical and resource use data, including 
efficacy, incremental mortality for NE-MRSA, adverse events, and length of hospital/
ICU stay. Cost and health utilities data were obtained from published literature. 
Base-case analysis used 2-day empiric, 10-day 1st/2nd-line treatment duration, 30% 
MRSA rate, and 1st line linezolid for NE-MRSA after culture confirmation. Patients 
with a negative culture for MRSA exited the model after empiric treatment, and 
were assigned a fixed cost for remaining treatment. Univariate and probabilistic 
sensitivity analyses were conducted. Costs were reported in 2014 USD. Results: 
Emp-LIN was associated with lower total costs ($41,975 vs. $42,288), and marginally 
greater QALY gain and overall treatment success compared to Emp-VAN, resulting in 
Emp-LIN ‘dominating’ Emp-VAN. Compared to NE-MRSA, Emp-LIN was more costly 
by $1,626, but had greater QALY gain (+0.836) and incremental treatment success 
(+5.9%), resulting in an incremental cost effectiveness ratio (ICER) of $1,946 per 
QALY gain, and $27,750 per successfully treated patient. Days in ICU stay, clinical 
efficacy, and MRSA rate had the greatest impact on ICER. Probability of Emp-LIN 
being cost-effective was 61% (vs. Emp-VAN) and 99% (vs. NE-MRSA) assuming a 
willingness-to-pay (WTP) of $50,000 per successfully treated patients and QALY gain 
respectively. ConClusions: Early treatment with Emp-LIN is a cost-effective alter-
native to Emp-VAN and NE-MRSA at reasonable WTP threshold, and should be con-
sidered a preferred treatment choice, especially at hospitals with high MRSA rate.
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objeCtives: Italian recommendations for human papillomavirus (HPV) immuni-
zation programmes currently target females only. However, males can be vectors 
in virus transmission and are at risk of disease infection. The BEST II study was 
designed to evaluate the cost-effectiveness (CE) of different interventions target-
ing females as well as males, and the economic impact of vaccination on a wide 
range of HPV-induced diseases. Methods: A dynamic Bayesian Markov model 
was developed to investigate HPV transmission between sexual partners and the 
cost-effectiveness of several HPV vaccination strategies. Both sexes were included 
in a universal vaccination programme which was compared to screening-only 
and female-only vaccination. A range of HPV-induced diseases was considered 
(cervical, vaginal, vulvar, anal, head/neck and penile cancer, the associated pre-
cancerous stages as well as anogenital warts). The process of sexual mixing was 
estimated based on age-, gender- and sexual behavioural-specific factors to esti-
mate the force of infection dynamically. The degree of susceptibility to the virus, 
associated with early sexual debut, high number of partners, smoking and previ-
ous STIs, was also included. We considered several scenarios; the baseline assumes 
universal vaccination to be implemented for 12-year-old females and males. The 
follow-up period was 55 years. Results: According to our preliminary analysis, 
universal vaccination resulted as a cost-effective alternative when compared to 
screening-only (with an incremental CE ratio, ICER, of € 1,200) and to female-only 
vaccination (ICER = € 6,900). We performed extensive sensitivity analyses to para-
metric assumptions, which confirmed the good CE profile of universal vaccination 
in Italy. ConClusions: Universal HPV vaccination of male and female cohorts is 
cost-effective compared to cervical screening and female-only vaccination, when 
accounting for a great variety of HPV-related diseases. This is mainly due to the 
fact that universal vaccination increases the effects of herd immunity and pro-
vides indirect protection against HPV.
PIN60
ecoNomIc eValuatIoN of fIdaxomIcIN for tHe treatmeNt of 
clostrIdIum dIffIcIle INfectIoNs (cdI) also KNowN as clostrIdIum 
dIffIcIle-assocIated dIarrHoea (cdad) IN sPaIN
Cobo Reinoso J.1, Grau Cerrato S.2, Mensa Pueyo J.3, Salavert Lletí M.4, Toledo A.5, Anguita P.5, 
Rubio-Terrés C.6, Rubio-Rodríguez D.6
1Infectious Diseases Department. Hospital Universitario Ramón y Cajal., Madrid, Spain, 
2Pharmacy Department. Hospital del Mar, Barcelona, Spain, 3Infectious Diseases Department. 
Hospital Clínic., Barcelona, Spain, 4Infectious Diseases Unit. Hospital La Fe., Valencia, Spain, 
5Astellas Pharma SA, Madrid, Spain, 6Health Value, Madrid, Spain
objeCtives: Fidaxomicin is the first in a new class of macrocylic antibiotics, 
indicated in adults for the treatment of Clostridium difficile infections (CDI). The 
objective was to analyse the cost-utility of fidaxomicin compared to oral van-
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initiating therapy could be a cost-effective option compared to a PI based initiating 
therapy in the Greek health care setting.
PIN66
loNg-term outcomes of ledIPasVIr/sofosbuVIr (ldV/ sof) for tHe 
treatmeNt of cHroNIc HePatItIs c INfected (HcV) geNotyPe 1 PatIeNts 
IN tHe uK
Guerra I.1, Marie L.2, Cure S.1
1OptumInsight, Uxbridge, UK, 2OptumInsight, Nanterre, France
objeCtives: Sofosbuvir (SOF) is a uridine analogue polymerase inhibitor. Ledipasvir 
(LDV) is an inhibitor of the hepatitis C virus (HCV) NS5A protein. Efficacy and safety 
have been demonstrated in three phase III clinical trials of LDV/SOF administered 
with or without ribavirin. This analysis evaluated the long-term outcomes of LDV/
SOF in GT1 treatment-naïve (TN) and treatment-experienced protease inhibitor 
failure patients (TE) HCV patients. Methods: A Markov-model followed 10,000 
patients for a lifetime, with 19% initiating treatment at the compensated cirrhotic 
(CC) stage. In GT1 TN, LDV/SOF for 8 weeks for non-cirrhotic (NC) patients and 12 
weeks for CC patients was compared against SOF with pegylated interferon 2a and 
ribavirin (SOF/PR), SOF with RBV (SOF/RBV) and simeprevir with PR (SMV/PR). In 
GT1 TE, LDV/SOF for 12 weeks was compared with SOF/PR, SMV/PR and no treat-
ment. SVR rates have been reported as 94% for GT1 TN NC and CC patients, 95% and 
86% for GT1 TE NC and CC respectively. SOF/LDV was also well tolerated without 
any reported grade 3/4 adverse events. Results: SOF/LDV was shown to be highly 
effective in preventing advanced liver disease (ALD) and mortality due to HCV. In 
GT1 TN, LDV/SOF prevented more than 800, 200 and 1600 cases of ALD than SMV/
PR, SOF/PR and SOF/RBV. In GT1 TE over 5000 cases of ALD were avoided compared 
with no treatment and over 1000 compared with SMV/PR, and SOF/PR. LDV/SOF was 
also shown to save more than 10 lives compared with SMV/PR, SOF/PR and SOF/
RBV and avoid the death of 50 TE PI failure patients with no available treatment 
option. ConClusions: LDV/SOF was shown to be highly effective in preventing 
progression to ALD and reducing HCV-related mortality with a well-tolerated single 
tablet regimen. This is particular important for protease inhibitor failure patients 
since there are currently no alternative treatment options.
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objeCtives: Sovaldi (sofosbuvir) is the first nucleotide polymerase inhibitor with 
pan-genotypic activity and a high barrier to resistance. Efficacy of sofosbuvir-
based regimens demonstrated > 90% SVR across genotype (GT) 1-6 in five phase 
III clinical trials of sofosbuvir administered with ribavirin or a combination of 
pegylated interferon alfa and ribavirin (PR). Sofosbuvir is also the first all-oral 
24-week option available for patients unsuitable for interferon (UI). This analy-
sis evaluated the cost-effectiveness and long-term outcomes of sofosbuvir in 
Swedish treatment-naïve genotype GT1/4/5/6 patients and GT2 and 3 patients 
who are treatment-naïve, treatment-experienced, interferon eligible (IE) and 
UI. Methods: A Markov-model followed 10,000 patients for a lifetime, with 20% 
initiating treatment at the compensated cirrhotic stage. For patients IE SOF/PR 
for 12 weeks was compared to telaprevir, boceprevir and PR, showing the highest 
SVR rates and a favourable safety profile. A societal perspective was adopted by 
considering productivity losses associated with treatment and advanced liver 
disease (ALD). Results: Sofosbuvir regimens, including interferon-free, were 
shown to be cost-saving across all genotypes and against all current treatment 
alternatives in Sweden. In GT1, this novel therapy incurs approximately 42%, 31% 
and 25% lower costs than PR, boceprevir and telaprevir, respectively. Sofosbuvir 
also reduces the burden of HCV. In 10,000 patients, we estimated that on average 
1697, 1417, 607 and 204 cases of compensated cirrhosis, decompensated cirrhosis, 
hepatocellular carcinoma and liver transplant, respectively, and 92 deaths could be 
avoided with sofosbuvir-based regimens compared with telaprevir, boceprevir, PR 
and no treatment. ConClusions: Cost-effectiveness analysis based on a Swedish 
societal perspective (i.e. including productivity losses due to treatment and ALD) 
shows sofosbuvir-based treatments to be cost saving in all genotypes and against 
all current treatment alternatives. In order to optimally allocate scarce societal 
resources, arguably all costs related to HCV treatment need to be included in the 
cost-effectiveness analysis.
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objeCtives: Other economic evaluation tools than the classical cost-effectiveness 
(CE) analysis exist but the acceptance of these by decision makers is unknown. We 
assessed the value of these new methods among experts and decision makers in 
Europe through a survey. Methods: Qualitative structured phone-interviews were 
conducted among experts and decision makers in eleven European countries over 
a one year period to evaluate the current and future use of additional economic 
evaluation methods for reimbursement decisions on vaccines. The five additional 
methods were: 1) Return on Investment (RoI); 2) Multi-Criteria Decision Analysis 
(MCDA); 3) Quality of hospital care (QoC); 4) Health care Budget Optimisation (BOM), 
and 5) Macro-Economic Analysis (MEA). Results: One hundred and seventy experts 
were contacted with a 15% participation rate (25 experts participated). In countries 
where CE is formally used like Belgium, the Netherlands, the UK and the Nordic 
countries, the additional methods were considered as relevant by most experts to 
value vaccines: RoI (61%), MCDA (62%), QoC (54%), BOM (54%) and MEA (61%). They 
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objeCtives: To evaluate the cost-effectiveness of commonly used antimicrobial reg-
imens in treatment of Community-acquired Pneumonia (CAP) in China. Methods: 
This was a retrospective study of CAP patients who received different antibiotic 
drugs during their hospitalization in a 1st Class, Grade A hospital in Shenyang, 
Liaoning between January 2011 and June 2012. Cost-effectiveness analysis was 
performed for the common therapeutic regimens based on both clinical practice 
and the main recommended antibacterial treatment of CAP from the perspective 
of society as a whole. For the sensitivity analysis, we used a relative measurement 
method and an absolute measurement method to test the strength of the study’s 
conclusions over a range of assumptions. Results: 203 clinical cases met study 
criteria, and were assigned to the groups of cefuroxime (n= 26), cefmetazole (n= 60), 
cefamandole (n= 32), moxifloxacin hydrochloride (n= 28), erythromycin (n= 28), 
cefmetazole and erythromycin (n= 29). The treatment success rate for the 6 groups 
were 42.31%, 51.67%, 6.25%, 25.0%, 60.71% and 65.52%, respectively, total direct medi-
cal costs were $474.10, $501.21, $1082.43, $1024.46, $404.15 and $555.84, respectively, 
among them, the incremental cost-effectiveness ratio (ICER) of erythromycin group 
and a combination regimen (cefmetazole plus erythromycin) was 31.54, indicating 
that erythromycin and combination of cefmetazole and erythromycin had a positive 
effect on treatment success and a lower total cost. Sensitivity analysis supported 
the dominance of the 2 groups in nearly all scenarios but the variation of treatment 
success rate. ConClusions: Erythromycin monotherapy and a combination of 
cefmetazole and erythromycin were more cost-effective than other regimens in the 
treatment of Community-acquired Pneumonia. Nevertheless, since there was no 
cost-effective threshold in China to compare the cost-effectiveness of the 2 options, 
it remains to be further researched and discussed.
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objeCtives: C. difficile is the leading cause of antibiotic associated infectious 
nosocomial diarrhoea. The two main treatments for these patients are fidaxomicin 
and vancomycin. In two phase III randomized controlled trials fidaxomicin was 
found to be non inferior to vancomycin in initial clinical cure of CDI and superior 
in preventing recurrences. The main goal of this economic analysis was to evaluate 
the cost-effectiveness of fidaxomicin versus vancomycin, for the treatment of C. 
difficile infection in Hungary. Methods: A decision tree model was developed to 
capture the consequences of recurrent infections with both treatment options. 
The model reported two clinical outcomes: clinical cure and recurrent CDI epi-
sodes. Treatment efficacy was estimated through a meta-analysis in a Bayesian 
framework. The model took the third party payer perspective. The incremental 
cost-effectiveness ratio was calculated as the ratio between costs and number of 
avoided recurrent episodes. Uncertainty around model parameters was assessed 
through probabilistic sensitivity analysis. Results: Total average costs for fidax-
omicin and vancomycin therapies were € 3,987 and € 2,505 per patient, respectively. 
The average number of recurrent episodes per patients was lower with fidaxomicin 
therapy (0.13 recurrent episodes/patient) than with vancomycin therapy (0.40 
recurrent episodes/patient). Incremental cost-effectiveness ratio (fidaxomicin 
vs. vancomycin) was € 5,520 per avoided recurrent episode. ConClusions: In 
conclusion, this study found that fidaxomicin has favourable cost-effectiveness 
ratio compared to vancomycin.
PIN65
cost-effectIVeNess aNalysIs of raltegraVIr IN HIV-INfected 
treatmeNt NaIVe PatIeNts IN greece
Athanasakis K.1, Boubouchairopoulou N.1, Retsa M.P.2, Maiese E.M.3, Elbasha E.H.4, 
Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2MSD Hellas, Athens, Greece, 3Merck & Co, Inc., 
Whitehouse Station, NJ, USA, 4Merck & Co, Inc, Flourtown, PA, USA
objeCtives: Despite the success of current antiretroviral therapies for human 
immunodeficiency virus (HIV) infection, the development of drug resistance repre-
sents a critical issue. Raltegravir is an inhibitor of HIV-1 integrase approved for treat-
ment experienced and naive patients. The present study aimed at conducting an 
economic evaluation of raltegravir vs protease inhibitor (PI) regimen in treatment-
naive patients in Greece. Methods: A three-stage continuous-time Markov model 
was developed using differential equations, for the cost-effectiveness analysis of 
initiating raltegravir-based therapy as first-line treatment vs initiating protease 
inhibitor (PI) -based therapy as first-line therapy, over a lifetime horizon. Stages of 
the model included progression through successive treatment therapies. Patients 
entered the model with a given CD4 cell count and HIV-1 viral load. After they failed 
or discontinued the current therapy, patients transitioned between eighteen health 
states (defined according to CD4-count and HIV-1 viral load), and progressed to the 
next stage. At any time they could develop acquired immunodeficiency syndrome 
(AIDS), suffer from a coronary heart disease (CHD) or die. Model inputs were col-
lected from the literature and adapted to Greek health care setting using expert 
opinion. Model outcomes included projected number of AIDS cases, number of 
CHD events, number of deaths, life expectancy and incremental cost-effectiveness 
ratios (ICER). The analysis was performed from the perspective of the Greek Social 
Insurance. Results: Patients initiating on the raltegravir-based therapy presented 
longer undiscounted life expectancy compared to those initiating on a PI regimen 
(21.20 vs 18.85 years). The ICER for a raltegravir-initiated treatment strategy vs. 
a boosted PI initiated treatment strategy was 12,757/QALY gained (discounted at 
3%). ConClusions: Results suggest that, over a lifetime horizon, raltegravir based 
